A carregar...
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a fatal disease with rising incidence in the world. For advanced HCC, sorafenib, a multikinase inhibitor, is the only systemic therapy with proven survival benefits. Sorafenib is a pan-VEGF receptor inhibitor, and thus many studies have focused its antivascular effe...
Na minha lista:
| Publicado no: | Immunotherapy |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5619018/ https://ncbi.nlm.nih.gov/pubmed/26865127 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt.15.126 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|